ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0098

CCL2 and CCR2 in Adult Onset Still’s Disease

Ju-Yang Jung1, Ji-Won Kim1, Chang-Hee Suh1 and Hyoun-Ah Kim1, 1Ajou university school of medicine, Suwon, Republic of Korea

Meeting: ACR Convergence 2020

Keywords: Still's disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster I: Diagnosis and Testing

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Adult onset Still’s disease (AOSD) is a rare systemic inflammatory disease characterized by a high spiking fever, evanescent rash, arthralgia, generalized lymphadenopathy, and leukocytosis. The activation of innate immune system is the main pathogenesis of AOSD. Chemokine C-C motif ligand (CCL) 2 and CC chemokine receptor (CCR) 2, a ligand of CCR2, have a chemical attractant activity and migrate monocyte and macrophages to the site of inflammation.

Methods: This study checked the serum levels of CCL2 and CCR2 in patients with AOSD and rheumatoid arthritis (RA), and healthy controls (HC), and analyzed their associations with clinical markers in patients with AOSD.

Results: The levels of CCL2 in serum were significantly increased in patients with AOSD (476.41 ± 689.06 pg/mL) compared in patients with RA (169.15 ± 118.71 pg/mL, p = 0.007) and HCs (135.14 ± 71.66 pg/mL, p = 0.003). The levels of CCR2 in serum were increased in AOSD patients rather than RA and HC, but it was not statistically significant because the large variation between individuals. The levels of CCL2 in serum was significantly increased in active group (589.49 ± 772.41 pg/mL) than inactive group (157.73 ± 71.02 pg/mL, p < 0.001) in patients with AOSD. The levels of CCL2 in serum correlated with systemic score (r = 0.539, p < 0.001), the counts of leukocyte (r = 0.316, p = 0.041) and neutrophil (r = 0.316, p = 0.041), C-reactive protein (r = 0.321, p = 0.044), ferritin (r = 0.607, p < 0.001), LDH (r = 0.597, p < 0.001) and albumin (r = -0.428, p = 0.005). However, the level of CCR2 in serum was not associated with any clinical markers of disease activity. After disease was resolved, the levels of CCL2 were significantly decreased in patients with AOSD (p = 0.029).

Conclusion: Circulating CCL2 was elevated in patients with AOSD and was associated with disease activity, suggesting that CCL2 might take a role in the inflammatory response of AOSD.


Disclosure: J. Jung, None; J. Kim, None; C. Suh, Celltrion, 5; H. Kim, None.

To cite this abstract in AMA style:

Jung J, Kim J, Suh C, Kim H. CCL2 and CCR2 in Adult Onset Still’s Disease [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/ccl2-and-ccr2-in-adult-onset-stills-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ccl2-and-ccr2-in-adult-onset-stills-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology